ISSN (Print) - 0012-9976 | ISSN (Online) - 2349-8846

A+| A| A-

As Good as a Leaky Bucket

Drug Price Control Order 2013

The hope that prices of medicines will reduce and super-profits will be curtailed has been belied by the government's drug control measures. As warned earlier, there are many loopholes which will keep most medicines out of price control, while manufacturers are likely to move away from controlled medicines to the production of unregulated ones. There is not even a proper mechanism to record and respond to consumer grievances.

A new Drug Price Control Order (DPCO 2013) was announced in May 2013. The simple average price control formula and other features of the National Pharma Pricing Policy (NPPP 2012) now find confirmation in DPCO 2013.

In an earlier piece in this journal (“Pharma Policy 2012 and Its Discontents”, EPW, 5 January 2013), we had shown how the ceiling price for medicines arrived at by the simple average formula has no relation to its cost of production, and would result in many “price-controlled” medicines continuing to be sold at high margins of 1000%-3000%. We had also commented on other problems with the NPPP 2012 – these of course continue in DPCO 2013. We briefly review some of them below – and point out some new problems in the DPCO 2013.

To read the full text Login

Get instant access

New 3 Month Subscription
to Digital Archives at

₹826for India

$50for overseas users

Comments

(-) Hide

EPW looks forward to your comments. Please note that comments are moderated as per our comments policy. They may take some time to appear. A comment, if suitable, may be selected for publication in the Letters pages of EPW.

Back to Top